Clinical study of lung-supplementing and stasis-dissolving decoction (Bufei Huayu Tang) combined with gefitnib for treatment of advanced non-small cell lung cancer.

To investigate the clinical efficacy and drug safety of Lung-Supplementing and Stasis-Dissolving Decoction (Bufei Huayu Tang) combined with gefitnib for treatment of advanced non-small cell lung cancer (NSCLC). Then, 80 patients with advanced NSCLC hospitalized in Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine were included, and were double-blindly randomized into 4 groups: control group (gefitinib alone 250mg, once daily), low-dose group (100mL/day), middle-dose group (150mL/day) and high-dose group (200mL/day) treated with different doses of Bufei Huayu Tang besides gefitinib. Clinical efficacy, life quality change before and after treatment, ECOG score, survival time and incidence of adverse drug reaction were compared. ECOG score in middle-dose group after treatment was significantly higher than other groups (P<0.05). Total efficiency of 4 groups was respectively 15%, 20%, 55% and 25%, and total efficiency in middle-dose group was significantly higher than that in other groups (P<0.05). According to TCM syndrome score, the improvement in middle-dose group was significantly better than that in other groups (P<0.05). Incidence of adverse drug reaction in high-dose group was significantly higher than that in other 3 groups (P<0.05). Self-designed Bufei Huayu Tang combined with gefitinib for NSCLC has a satisfactory clinical efficacy and high drug safety. Decoction dose needs more attention.

RCT Entities:   Population Interventions Outcomes